Figure 5. Capsule shedding as a function of antimicrobial peptides or capsule serotype.

(a) TIGR4 was treated with LL-37 (4 μg ml⁻¹), human β-defensin 3 (hβD-3) at the indicated concentration, nisin (64 μg ml⁻¹) or polymyxin B (32 μg ml⁻¹). The supernatants from these assays were then analysed by capsule blot. n/a: no addition. (b) Serotypes 6A and 3 strains were subjected to the shedding assay with LL-37 (4 μg ml⁻¹) and the supernatants were analysed by capsule blot.